Viewing Study NCT04675294

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:31 AM
Ignite Modification Date: 2026-03-06 @ 9:57 AM
Study NCT ID: NCT04675294
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-01
First Post: 2020-12-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Sponsor: ALX Oncology Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Head and Neck Cancer View
None Head and Neck Squamous Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ALX148 View
None CD47 View
None SIRPĪ± View
None HNSCC View
None pembrolizumab View
None evorpacept View